Agents in late-stage development for the treatment of hospital-acquired pneumonia, Clostridium difficile-associated diarrhea, and complicated skin and skin-structure infections.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.